Steven Valiquette
Stock Analyst at Mizuho
(3.62)
# 822
Out of 5,056 analysts
119
Total ratings
59.38%
Success rate
4.16%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Neutral | $5 → $4 | $2.79 | +43.37% | 1 | Nov 6, 2025 | |
| COR Cencora | Maintains: Outperform | $340 → $380 | $361.64 | +5.08% | 3 | Nov 6, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $170 → $210 | $206.97 | +1.46% | 7 | Nov 4, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $48 → $50 | $34.87 | +43.39% | 2 | Oct 30, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $210 → $170 | $132.28 | +28.52% | 12 | Oct 13, 2025 | |
| MCK McKesson | Maintains: Neutral | $750 → $770 | $860.75 | -10.54% | 4 | Sep 24, 2025 | |
| VEEV Veeva Systems | Maintains: Outperform | $295 → $325 | $273.72 | +18.73% | 4 | Aug 29, 2025 | |
| PHR Phreesia | Initiates: Outperform | $36 | $19.60 | +83.67% | 1 | Aug 27, 2025 | |
| NVST Envista Holdings | Maintains: Underperform | $15 → $18 | $19.13 | -5.91% | 2 | Aug 1, 2025 | |
| TDOC Teladoc Health | Initiates: Neutral | $10 | $7.00 | +42.86% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $60 | $47.42 | +26.53% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $18 | $10.26 | +75.44% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $82 | $76.89 | +6.65% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $4.09 | +71.15% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $102.74 | +22.64% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $75 | $71.20 | +5.34% | 5 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.11 | +60.77% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $14 | $2.89 | +384.43% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $228.84 | -37.95% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $79.86 | -31.13% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $198.29 | -53.60% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $313.58 | +80.18% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $77.94 | +28.30% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $5.10 | +174.51% | 1 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $141.19 | +183.31% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $36.93 | +189.74% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $36.91 | -53.94% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $10.57 | +13.53% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $112.67 | -14.80% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $185.32 | -35.25% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $478.14 | -73.44% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $234.10 | +52.93% | 3 | Dec 6, 2019 |
GoodRx Holdings
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $2.79
Upside: +43.37%
Cencora
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $361.64
Upside: +5.08%
Cardinal Health
Nov 4, 2025
Maintains: Outperform
Price Target: $170 → $210
Current: $206.97
Upside: +1.46%
Waystar Holding
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $34.87
Upside: +43.39%
Align Technology
Oct 13, 2025
Maintains: Outperform
Price Target: $210 → $170
Current: $132.28
Upside: +28.52%
McKesson
Sep 24, 2025
Maintains: Neutral
Price Target: $750 → $770
Current: $860.75
Upside: -10.54%
Veeva Systems
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $273.72
Upside: +18.73%
Phreesia
Aug 27, 2025
Initiates: Outperform
Price Target: $36
Current: $19.60
Upside: +83.67%
Envista Holdings
Aug 1, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $19.13
Upside: -5.91%
Teladoc Health
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $7.00
Upside: +42.86%
May 16, 2025
Maintains: Neutral
Price Target: $65 → $60
Current: $47.42
Upside: +26.53%
Mar 13, 2025
Maintains: Neutral
Price Target: $21 → $18
Current: $10.26
Upside: +75.44%
Mar 3, 2025
Maintains: Neutral
Price Target: $70 → $82
Current: $76.89
Upside: +6.65%
Dec 4, 2024
Initiates: Neutral
Price Target: $7
Current: $4.09
Upside: +71.15%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $102.74
Upside: +22.64%
Dec 4, 2024
Initiates: Neutral
Price Target: $75
Current: $71.20
Upside: +5.34%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $3.11
Upside: +60.77%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $18 → $14
Current: $2.89
Upside: +384.43%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $228.84
Upside: -37.95%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $79.86
Upside: -31.13%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $198.29
Upside: -53.60%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $313.58
Upside: +80.18%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $77.94
Upside: +28.30%
Feb 27, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $5.10
Upside: +174.51%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $141.19
Upside: +183.31%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $36.93
Upside: +189.74%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $36.91
Upside: -53.94%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $10.57
Upside: +13.53%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $112.67
Upside: -14.80%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $185.32
Upside: -35.25%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $478.14
Upside: -73.44%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $234.10
Upside: +52.93%